Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 5;6(4):00143-2020.
doi: 10.1183/23120541.00143-2020. eCollection 2020 Oct.

ERS International Congress, Madrid, 2019: highlights from the Interstitial Lung Diseases Assembly

Clairelyne Dupin  1 , Vânia Fernandes  2 , Fernanda Hernandez-Gonzalez  3 , Sebastiano Emanuele Torrisi  4   5 , Tiago M Alfaro  2 , Michael Kreuter  5 , Marlies S Wijsenbeek  6 , Elisabetta A Renzoni  7   8   9 , Elena Bargagli  10 , Hilario Nunes  11   12 , Paolo Spagnolo  13 , Francesco Bonella  14 , Maria Molina-Molina  15   16   17 , Katerina Antoniou  18 , Venerino Poletti  19   20
Affiliations
Review

ERS International Congress, Madrid, 2019: highlights from the Interstitial Lung Diseases Assembly

Clairelyne Dupin et al. ERJ Open Res. .

Abstract

This article discusses a selection of the scientific presentations in the field of interstitial lung diseases (ILDs) that took place at the 2019 European Respiratory Society International Congress in Madrid, Spain. There were sessions from all four groups within Assembly 12: group 12.01 "Idiopathic interstitial pneumonias", group 12.02 "ILDs/diffuse parenchymal lung diseases (DPLDs) of known origin", group 12.03 "Sarcoidosis and other granulomatous ILDs/DPLDs" and group 12.04 "Rare ILDs/DPLDs". The presented studies brought cutting-edge developments on several aspects of these conditions, including pathogenesis, diagnosis and treatment. As many of the ILDs are individually rare, the sharing of experiences and new data that occur during the Congress are very important for physicians interested in ILDs and ILD patients alike.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: C. Dupin reports grants from AstraZeneca, GSK and Sanofi, personal fees and non-financial support from AstraZeneca, Chiesi, GSK, Roche and Sanofi, non-financial support from Boehringer, and personal fees from Novartis, all outside the submitted work. Conflict of interest: V. Fernandes has nothing to disclose. Conflict of interest: F. Hernandez-Gonzales has nothing to disclose. Conflict of interest: S.E. Torrisi has nothing to disclose. Conflict of interest: T.M. Alfaro has nothing to disclose. Conflict of interest: M. Kreuter reports grants and personal fees from Boehringer and Roche, and personal fees from Galapagos, outside the submitted work. Conflict of interest: M.S. Wijsenbeek reports grants from Boehringer Ingelheim and Hoffman la Roche, and other support from Boehringer Ingelheim, Hoffman la Roche, Galapagos and Respivant, all paid to her institution and all outside the submitted work. Conflict of interest: E.A. Renzoni reports lecture and advisory board fees from Roche and Boehringer Ingelheim, outside the submitted work. Conflict of interest: E. Bargagli has nothing to disclose. Conflict of interest: H. Nunes reports consultancy and research support fees from Roche/Genentech and Boehringer Ingelheim, personal fees for serving as an expert for a clinical end-point committee from Galapagos, and other support for serving as an investigator on clinical trials from Sanofi, Gilead, Novartis and Galecto Biotech AB, and for service as a board expert on a clinical trial from Actelion Pharmaceuticals, during the conduct of the study. Conflict of interest: P. Spagnolo reports grants, personal fees and non-financial support from Roche, PPM Services and Boehringer Ingelheim, and personal fees from Red X Pharma, Galapagos and Chiesi, all outside the submitted work; additionally, his wife is an employee of Novartis. Conflict of interest: F. Bonella reports grants, personal fees and non-financial support from Boehringer Ingelheim, Roche and Galapagos, and grants and personal fees from Savara, outside the submitted work. Conflict of interest: M. Molina-Molina reports grants and personal fees from Roche, Boehringer Ingelheim and Esteve-Teijin, and personal fees from Chiesi and Pfizer, outside the submitted work. Conflict of interest: K. Antoniou has nothing to disclose. Conflict of interest: V. Poletti has nothing to disclose.

Similar articles

See all similar articles

References

    1. Noth I, Maher TM, Johannson KA, et al. . Adherence to home spirometry among patients with IPF: results from the INMARK trial. Eur Respir J 2019; 54: Suppl. 63, PA2241.
    1. Moor K, Visser L, Aerts J, et al. . Diurnal variation in forced vital capacity in patients with fibrotic interstitial lung disease using home spirometry: the DIVA study. Eur Respir J 2019; 54: Suppl. 63, PA2246. - PMC - PubMed
    1. Maher T, Corte TJ, Fischer A, et al. . Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD (uILD). Eur Respir J 2019; 54: Suppl. 63, RCT1880.
    1. Jouneau S, Crestani B, Thibault R, et al. . Relationship between body mass index (BMI) and decline in FVC in patients with IPF. Eur Respir J 2019; 54: Suppl. 63, PA2252.
    1. Torrisi SE, Hyldgaard C, Kahn N, et al. . Prognostic impact of radiological findings in unclassifiable interstitial lung diseases. Eur Respir J 2019; 54: Suppl. 63, PA2247.

LinkOut - more resources